Ambrose Healthcare Exercise Option on VAL 401 Out License Agreement for £16 Million plus Royalties
Ambrose Healthcare Exercise Option on VAL 401 Out License Agreement for £16 Million plus Royalties
New Response in the FAP-Dox (AVA6000) Phase 1b Trial
SkinBioTherapeutics signs exclusive commercial agreement with Superdrug for AxisBiotix™ products in the UK Placing and Subscription to raise £4.1m to support Superdrug agreement; Proposed Retail Offer to existing shareholders of
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines, announces that further to the 6 June 2025 announcement, it
New SlimBiome® study published in European Journal of Nutrition
Totally PLC has announced its intention to appoint administrators and has suspended trading in its shares on AIM with immediate effect.
Preliminary Results for the Year Ended December 31, 2024
Update on timing of preliminary results announcement
Second Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin ‘Mo’ Khan, Chief
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it has received notification of a significant human challenge